Areas of interest

Bristol Myers Squibb has pioneered transformational medicines and is committed to sustaining its strong leadership and legacy in the development of transformational therapeutics for treating patients with malignant and benign hematological conditions.

• Our focus is on Multiple Myeloma, Lymphoma and CLL, AML, MDS,  MPNs (e.g., myelofibrosis) and non-malignant conditions (e.g., thalassemias)

Areas of interest include, but are not limited to, the following:

• Targeted protein degradation/homeostasis
• Epigenetics
• ADCs, including ADC degraders, immune cell engagers and other novel antibody constructs
• Targeting molecularly defined patient segments
• Next generation therapies with differentiated safety and efficacy profiles
• Novel therapeutic targets/pathways and  combinations
• Targeting pathways of resistance

Learn more about hematology compounds in pipeline.

Leveraging longstanding expertise, Bristol Myers Squibb has pioneered some of the most significant advancements in cardiovascular care and delivered transformational results for patients. We are building on our 70-year legacy to take cardiovascular research to the next level and elevate new standards of care.  Our differentiated scientific discovery engine, rooted in causal human biology, focuses on accelerating the next generation of precision therapies that improve both clinical outcomes and quality of life. These include disease-modifying medicines that are designed to help patients living with arterial thrombosis, types of heart failure, cardiomyopathies, and residual risk of vascular disease in ways that were never possible before.

Areas of interest include, but are not limited to, the following:

• BMS continues to monitor the obesity market for next generation assets with cardiovascular impact
• Novel targets and/or cardiac specific delivery modalities addressing specific cardiomyopathies (e.g., genetically defined targets)
• Modulators of cardiac sarcomere function, activation and inhibition
• Cardiac gene insufficiency caused by loss of function mutations
• Cardiac myocyte proteotoxicity caused by protein mutations or misfolding, sarcomere homeostasis
• Protection against or regression of adverse remodeling of the heart (e.g., fibrosis, hypertrophy, resolution of inflammation, cardiomyocyte preservation or regeneration)
• Novel mechanisms to target heart failure
• Preservation or improvement of renal function/renal perfusion in heart failure patients
• Improvement of peripheral vascular compliance
• Reduction in residual atherosclerotic risk driven by poorly or untreated dyslipidemias and/or vascular inflammation
• Translational tools for patient selection within more precisely defined target populations

Learn more about cardiovascular compounds in pipeline.

Bristol Myers Squibb is pursuing pathbreaking science in Immunology to deliver meaningful solutions that address unmet needs in rheumatology, pulmonology, dermatology and gastroenterology.

• Our team has spent the last two decades pioneering research on novel pathways and approaches, resulting in new therapies that modulate the body’s immune response to treat disease
• Today, Bristol Myers Squibb’s Immunology franchise encompasses several marketed products and a robust pipeline in clinical development, including rheumatoid arthritis, systemic lupus erythematosus (SLE), pulmonary fibrosis, psoriasis and other immune-mediated diseases with high unmet needs
• Our strategic research approach aims to addresses the root cause of disease by controlling inflammation, resetting the immune system and promoting immune homeostasis with the goal of achieving transformational efficacy, durable remissions, and ultimately, cures

Areas of interest include, but are not limited to, the following:

• Agents that target selective immune suppression, eliminate pathogenic immune memory cells and/or promote immune homeostasis, including those that act on both immune and non-immune cell types (e.g., epithelial and stromal cells)
• Progressive pulmonary fibrotic diseases including Idiopathic Pulmonary Fibrosis and non-IPF Interstitial Lung Diseases such as scleroderma
• Mechanisms which promote repair and reversal of fibrosis through inhibition of inflammatory responses, protection of epithelium and normalization of fibroblast activation
• Novel therapeutic modalities that selectively leverage tissue restricted or genetically validated targets
• Biomarkers of disease activity to inform patient stratification, measure pharmacodynamic responses and predict efficacy, with a particular interest in such biomarker-enabled programs

Learn more about immunology compounds in pipeline.

Bristol Myers Squibb is committed to the development of transformational therapeutics for patients living with neurological and neuropsychiatric diseases, with a focus on conditions with critical unmet needs. We work to develop life-changing medicines that modify disease and treat symptoms to improve quality of life.

• We have established an innovative neuroscience pipeline with assets across a breadth of modalities, accelerated by our growing leadership in neuropsychiatry. Our agile neuroscience research and development model is designed to cultivate a growing pipeline of differentiated drug candidates and deliver meaningful therapies for patients
• We combine internal expertise—including industry-leading development capabilities, an in-house neuroimaging program, world-class clinical trial operations capabilities, and a strong emphasis on translational research—with flexible external collaborations to identify and advance the most promising scientific innovation happening across the globe and deliver transformational results for our patients

Areas of interest include, but are not limited to, the following:

• Disease-modifying therapies for Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), repeat expansion diseases and progressive forms of multiple sclerosis
• Novel therapies for psychiatric disorders such as schizophrenia, major depressive disorder and bipolar mania where there are symptom domains of high unmet medical need and potential to improve patient outcomes
• Novel therapies for psychiatric disorders such as schizophrenia, major depressive disorder and bipolar 1 disorder where there are symptom domains of high unmet medical need and potential to improve patient outcomes
• Targets that modulate brain circuitry underlying psychiatric and neuropsychiatric diseases, protein homeostasis, protein clearance, immune system biology, and neuroinflammation and that reduce, eliminate or clear neurotoxic proteins
• Emerging technologies (RNA, DNA targeting, gene regulation, editing and replacement, delivery vector optimization) that when matched to underlying disease genetics, can deliver a precision medicine portfolio with a high probability of success to address unmet medical needs
• Novel blood brain-barrier shuttle technologies
• Cell therapies for neuroimmune regulation and reset or CNS neuron replacement for conditions such as Parkinson’s disease
• Translational tools
  • Novel translational biomarkers (Tissue-, imaging-, sensor-based) for detection, staging and monitoring progression of early disease
  • Novel methodologies for establishing clinical meaningfulness of novel drug candidates as early as possible in disease

Learn more about neuroscience compounds in pipeline.

At Bristol Myers Squibb, hundreds of world-class researchers make up the Translational Medicine team, spanning all therapeutic areas of focus from early discovery to commercialization. Leveraging genomics, proteomics, imaging, and bioinformatics, these researchers bring forward new learnings and solutions in efforts to revolutionize treatment strategies for some of the most challenging diseases.

Areas of interest include, but are not limited to, the following:

• Innovative biomarker applications to inform target identification, disease characterization and treatment optimization:
  • Diagnostic approaches to stratify/select patients most likely to benefit from therapy
  • Pharmacodynamic assessment of dose and treatment response
  • Biomarkers of emerging or novel clinical endpoints (e.g., minimal residual disease)
  • Technologies and systems to elucidate disease biology (including the tumor microenvironment) and mechanisms of resistance
• Biomarker and bioanalytical technologies and platforms:
  • Novel histopathology approaches; multiplexed fluorescence-based platforms and digital pathology and imaging analysis software applications
  • Multicolored flow cytometry assays (exploratory and diagnostic grade), for both peripheral and tumoral assessment
  • Proteomic technologies including high-resolution or high-plex applications
  • Genomic-based platforms covering qPCR, ddPCR and NGS: gene expression profiling and tumor and germline DNA deep sequencing; spatial transcriptomics and single-cell RNAseq;, methylation and epigenomic profiling;, liquid biopsy applications (cfDNA and cfRNA)
  • Novel radiomic imaging capabilities and alternate tracer platforms

Bristol Myers Squibb is committed to enhancing our discovery and development efforts through innovative technologies. We are approaching biology as a computational challenge, utilizing predictive science to decode complex biological systems and accelerate our research and development.

Areas of interest include, but are not limited to, the following:

• Targeted protein degradation technology and platforms
• Single cell genomics and proteomic platforms
• Label-free cellular target engagement platforms
• Stable cell lines to improve protein titer and quality attributes
• Platforms and engineered cell lines focused on cell and gene therapy applications and delivery systems (viral and non-viral); BBB delivery; delivery using payloads
• ADCs: novel targets, including post- translationally modified forms, with a strong link to cancer biology and reasonable pre-clinical data
• Novel MOA payloads for ADC’s including TOPO1 inhibitors
• Access to new chemical matter, including macrocycle and fragment libraries
• Novel discovery platforms, including target discovery modalities and platforms focused on neuromuscular and neurodegenerative disease
• Shape emerging protein structure determination platforms 
• Microfluidics based platforms that enable high throughput functional assays and sorting 
• Super resolution imaging platforms (such as 3D bioprinter, intelligent image analysis tools, tissue imaging and real-time single cell sorting/ purification based on machine learning)
• Technologies directed toward enhancing GI absorption of poorly absorbed compounds or enabling novel delivery methods (colonic, intraoral, subcutaneous, intra-tumoral) 
• Solid state stabilization of proteins to enable high-concentration parenteral delivery 
• Controlled release technologies for drug delivery
• Drug delivery device technologies
• Machine learning capabilities applied to research and early development
• Systems biology tools to evaluate pharmacologic/toxicologic responses
• Translationally relevant preclinical models
• Companion digital therapeutics that enhance delivery of care
• Peptide permeability enabling technologies